Medscape

Perioperative Pembrolizumab Approved to Up Chance of HNSCC Cure

The FDA has approved a before and after surgery regimen for pembrolizumab to improve outcomes in resectable locally-advanced head and neck squamous cell carcinoma (HNSCC). Specifically, the new ...
Monthly Prescribing Reference

Keytruda Gains HNSCC Indication for Perioperative Treatment

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care. The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) for the ...
Healio

Perioperative immunotherapy ‘a new frontier’ for head, neck cancer

Please provide your email address to receive an email when new articles are posted on . Adding perioperative pembrolizumab to standard of care significantly improved EFS for patients with advanced ...
EurekAlert!

Adding perioperative pembrolizumab to standard of care improves outcomes in patients with newly diagnosed head and neck cancer

CHICAGO – Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in patients with previously untreated, locally advanced head and neck ...
Nasdaq

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients ...

KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) Results to be presented at American ...
MedPage Today

New Standard of Care in Locally Advanced Head and Neck Cancer

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck squamous cell carcinoma (HNSCC) prolonged event-free survival (EFS), the ...